- Published on
KembaraXtra- Medicine – Alcohol Use Disorder
Alcohol use disorder (AUD) describes problematic patterns of alcohol use that lead to clinically significant impairment or distress, and it includes a spectrum from hazardous use to dependence and withdrawal syndromes. “Moderate drinking” is commonly defined as up to two standard drinks per day for men and one standard drink per day for women and adults older than 65 years. “Hazardous” or “at-risk” drinking is defined as more than 14 drinks per week or more than 4 drinks per occasion for men, and 4 or more drinks on one occasion or 8 or more drinks per week for women. Alcohol withdrawal is defined by the development of characteristic symptoms after cessation or reduction of heavy and prolonged alcohol use, including autonomic hyperactivity, tremor, insomnia, nausea/vomiting, transient hallucinations or illusions, psychomotor agitation, anxiety, and grand mal seizures; symptoms must cause clinically significant distress or impairment and not be better explained by another condition.
AUD is also referred to as alcohol dependence syndrome, alcoholism, substance abuse, and alcohol withdrawal syndrome. ICD-10-CM codes fall under F10 (mental and behavioral disorders due to alcohol use), including F10.1 (harmful use), F10.2 (dependence syndrome), F10.3 (withdrawal state), F10.4 (withdrawal state with delirium), F10.5 (psychotic disorder), and F10.6 (amnesic syndrome). In U.S. clinical settings, alcohol-related problems are suggested by the clinical history in roughly 15% to 20% of primary care and hospitalized patients, with substantial economic and health impacts. AUD prevalence in adults (≥18 years) is commonly cited around 7%, with peak incidence in early adulthood and a common initial treatment age range in the mid-30s to mid-40s. Lifetime risk is higher in men than women. Risk is increased by family history, and AUD is more common in certain ancestry groups as described in clinical epidemiology summaries.
Patients may present with a wide range of physical and clinical findings related to intoxication, chronic use, or complications. Common clinical clues include recurring minor trauma, gastrointestinal bleeding from gastritis or varices, pancreatitis (acute or chronic), liver disease, alcohol odor on breath, tremulousness, tachycardia, peripheral neuropathy, and recent memory loss. Etiology is multifactorial, with both genetic and social determinants contributing. Commonly described risk factors include unstable social environments, unemployment, divorce, recurrent depression, addiction to other substances (including tobacco), and occupational patterns such as working very long hours.
Diagnosis and initial evaluation rely heavily on screening and history. Screening tools commonly used include CAGE, AUDIT-C, TWEAK/TACE (especially in pregnancy), and CRAFFT (adolescents). CAGE asks about the need to cut down, annoyance by criticism, guilt, and eye-openers; a positive screen should prompt further assessment. AUDIT-C focuses on alcohol frequency and quantity and provides a structured score (0–12), with ≥4 in men and ≥3 in women suggesting problematic drinking requiring more evaluation. A single-question screen (“When was the last time you had more than X drinks in a day?” where X is 5 for men and 4 for women) can also identify unhealthy use when anchored to a recent timeframe. Laboratory tests alone do not diagnose AUD but are useful for identifying complications and nutritional deficiencies. Common findings include elevated gamma-glutamyltransferase (GGT), abnormal AST/ALT (which may be normal or low in advanced liver disease), low albumin, electrolyte abnormalities (hypophosphatemia, hypomagnesemia), macrocytosis with elevated MCV on CBC, positive stool occult blood when gastritis/varices are present, and low vitamin levels including folate, B12, B6, and especially thiamine (B1). Imaging is not routinely required unless trauma is suspected; abdominal ultrasound or CT may show fatty liver or cirrhosis in advanced disease.
Nonpharmacologic treatment is a foundation of care and includes structured psychosocial therapies such as twelve-step facilitation, cognitive behavioral therapy, and motivational enhancement therapy. Coexisting depression should be treated alongside alcohol cessation rather than delayed, because mood disorders commonly coexist and influence relapse risk. Detoxification is not sufficient as stand-alone care and should function as a bridge into a longer-term treatment plan.
Alcohol withdrawal syndrome is managed based on severity and timing from the last drink. Blood ethanol typically declines at about 20 mg/dL per hour. Early withdrawal (“tremulous state”) often begins within 6 to 8 hours after the last drink (or 12 to 48 hours after reduction), peaking around 24 to 36 hours, with tremor, insomnia, mild agitation, and tachycardia. Depending on support system, comorbidities, and risk factors for severe withdrawal, detoxification may occur in outpatient or inpatient settings. Inpatient care includes monitoring (often with standardized withdrawal charts), seizure precautions, and symptom-titrated sedation. Benzodiazepines are the cornerstone of withdrawal management and are used either as fixed-dose tapers or symptom-triggered regimens. Symptom-triggered protocols often use the CIWA-Ar scale to guide dosing; patients with mild symptoms can sometimes be monitored outpatient, while higher CIWA-Ar scores and high-risk histories warrant inpatient detoxification. Beta-blockers can help control tachycardia and hypertension but should not be used alone because they do not prevent seizures or delirium; clonidine can reduce autonomic symptoms in mild to moderate cases but similarly does not prevent seizures or delirium. Vitamin replacement is essential, especially thiamine, and thiamine should be administered before IV dextrose to reduce the risk of precipitating Wernicke encephalopathy. Hydration and correction of electrolytes (including magnesium and phosphate) are often required.
Alcoholic hallucinosis consists of predominantly auditory hallucinations (sometimes visual/tactile/olfactory) that often peak 24 to 36 hours after abstinence and can resemble a primary psychotic disorder, but typically occurs without the marked clouding of sensorium seen in delirium tremens. Withdrawal seizures usually occur within 7 to 30 hours after cessation (often peaking around 13 to 24 hours) and are typically generalized; focal deficits, prolonged confusion, or fever should prompt evaluation for alternative causes (including imaging and lumbar puncture when indicated). Delirium tremens (DTs) is the most severe withdrawal state, usually occurring within the first week after reduction or cessation of heavy intake, commonly peaking around 72 to 96 hours, and characterized by profound confusion, tremor, vivid hallucinations, and marked autonomic hyperactivity; untreated mortality is significant. DTs require close monitoring, aggressive supportive care, and adequate benzodiazepine sedation (sometimes with agents such as lorazepam, chlordiazepoxide, diazepam, or midazolam in titratable settings), along with correction of fluids, electrolytes, and coexisting medical problems.
Long-term (chronic) treatment focuses on relapse prevention and sustained recovery using both psychosocial support and, when appropriate, pharmacotherapy. Acamprosate supports maintenance of abstinence after detoxification and is typically dosed as 666 mg three times daily; it should be avoided in severe renal impairment. Naltrexone (oral or extended-release monthly injection) reduces the rewarding effects of alcohol and can reduce heavy drinking; it must be avoided in acute hepatitis/hepatic failure and in people using opioids, as it can precipitate opioid withdrawal. Disulfiram causes an aversive reaction to alcohol ingestion by blocking aldehyde dehydrogenase, but is now used less often. Agents such as topiramate, baclofen, or gabapentin may be considered second line in moderate to severe AUD, with some guidance suggesting topiramate may be preferable in certain cases. Pharmacologic therapy is generally avoided in pregnant or breastfeeding individuals.
Disposition and referral are key components of management. Community supports such as Alcoholics Anonymous, Adult Children of Alcoholics, and family supports like Al-Anon or Al-A-Teen can be helpful. Inpatient detoxification is relatively indicated for patients with a history of DTs or withdrawal seizures, severe withdrawal symptoms, significant psychiatric or medical comorbidities, pregnancy, multiple prior detoxifications, recent high levels of alcohol intake, or lack of a reliable support network. Even when detoxification is successful, long-term outcomes depend heavily on engagement in ongoing treatment and social support, because relapse is common without sustained intervention.
0 Comments
